Skip to content

ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

 
  • En
  • Sv
  • About us
    • Management
    • Board of Directors
  • Therapeutic areas
    • Liver metastases
    • Gastric Cancer
  • Pipeline
    • Orviglance®
    • Oncoral
  • Partnering
  • Investors
    • Press releases
    • Financial reports
    • Presentations & articles
    • Events
    • Share information
    • Shareholders
    • Insiders
    • Equity research
    • Financial calendar
  • Governance
    • General Meeting
    • Articles of Association
    • Nomination Committee
    • Board of Directors
    • Audit Committee
    • Remuneration Committee
    • Commercialization Committee
    • Remuneration
    • Auditors
    • Internal control
  • Career
    • Open positions
    • Our values
  • Contact
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
Subscribe to press releases
All All press releasesRegulatory press releasesFinancial reports
Regulatory
2025-05-07 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025
PDF
Report
Presentation
Webcast
Regulatory
2025-02-25 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 25 February 2025
PDF
Report
Presentation
Webcast
Regulatory
2024-10-30 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 30 October 2024
PDF
Report
Presentation
Webcast
Regulatory
2024-08-14 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 14 August 2024
PDF
Report
Presentation
Webcast
Regulatory
2024-05-06 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2024
PDF
Report
Presentation
Webcast
Regulatory
2023-11-13 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 13 November 2023
PDF
Report
Presentation
Webcast
Regulatory
2023-05-04 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2023
PDF
Report
Presentation
Webcast
Regulatory
2022-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022
PDF
Report
Presentation
Webcast
Regulatory
2021-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2021
PDF
Report
Presentation
Webcast
Regulatory
2021-04-13 | Bulletin from the extraordinary general meeting in Ascelia Pharma AB
PDF
Report
Presentation
Webcast
Regulatory
2020-05-06 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2020
PDF
Report
Presentation
Webcast
Regulatory
2019-11-14 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 14 November 2019
PDF
Report
Presentation
Webcast
Learn more

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. […]
Learn more

Contact

Today, on 14 November 2019, an annual general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority.Resolution on adoption of accounts and allocation of the company's result The annual general meeting resolved to adopt the income statement and balance s ...
Learn more

Our values

Our values inspire our ambitions, decision making and collaboration to help us reach our highest potential. INTEGRITY We build powerful relationship with mutual respect and adhere to the high ethical […]
  1. Start (en)

About us

  • Start (en)
  • About us
  • Career
  • Contact
  • Privacy policy
  • About cookies
  • Cookie settings
  • IMPORTANT INFORMATION

Pipeline

  • Oncoral
  • Orviglance®

IR & Media

  • Subscribe to press releases
  • Press releases & News
  • Financial Reports

Contact us

Ascelia Pharma AB
Hyllie Boulevard 34
215 32 Malmö
Sweden
Phone: +46 735 17 91 18

info@ascelia.com

Follow us

 

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development.

Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

© Copyright 2021 - Ascelia Pharma AB | We use cookies to improve our services | Disclaimer Market data could be delayed. Delivered by Modular Finance.

Video
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all